

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5249762

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALBANY MOLECULAR RESEARCH, INC.	07/12/2018
RECEIVING PARTY DATA	
Name:	CORBUS PHARMACEUTICALS, INC.
Street Address:	500 RIVER RIDGE DRIVE
City:	NORWOOD
State/Country:	MASSACHUSETTS
Postal Code:	02062
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16198381
CORRESPONDENCE DATA	
Fax Number:	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 428-0200
Email:	patentadministrator@clarkelbing.com
Correspondent Name:	CLARK & ELBING LLP
Address Line 1:	101 FEDERAL STREET
Address Line 2:	15TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	51186-005008
NAME OF SUBMITTER:	JEFFREY J. ELLISON, PH.D.
SIGNATURE:	/Jeffrey J. Ellison, Ph.D./
DATE SIGNED:	11/23/2018
Total Attachments: 5	
source=Executed Assignment (AMRI to Corbus)#page1.tif	
source=Executed Assignment (AMRI to Corbus)#page2.tif	
source=Executed Assignment (AMRI to Corbus)#page3.tif	
source=Executed Assignment (AMRI to Corbus)#page4.tif	
source=Executed Assignment (AMRI to Corbus)#page5.tif	

ASSIGNMENT

For good and valuable consideration, the sufficiency of which is hereby acknowledged, we,

Full Name of Assignor	State of Incorporation	Business Address
Albany Molecular Research, Inc.	Delaware	26 Corporate Circle Albany, NY 12203

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
Corbus Pharmaceuticals, Inc.	Delaware	500 River Ridge Drive Norwood, MA 02062

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent and/or applications in a foreign jurisdiction signed by us, identified as:

Title of Application	Filing Date	Serial Number	Country
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2013	61/763,630	US
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	June 21, 2013	61/837,743	US
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	July 26, 2016	15/220,127	US
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	November 9, 2016	15/347,059 (US Patent No. 9,801,849)	US
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	November 9, 2016	15/347,104 (US Patent No. 9,820,964)	US
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	September 7, 2017	15/698,544	US
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	PCT/US2014/016050	WO
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	AU2014216440	AU
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	BR1120150191800	BR
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	CA2900982	CA

ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	CN201480020828.1	CN
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	EP14752090.2	EP
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	JP2015-557221	JP
ULTRAPURE TETRAHYDROCANNABINOL -11-OIC ACIDS	February 12, 2014	KR10-2015-7024773	KR

and all patents, divisions, reissues, continuations and any extensions thereof and rights of priority therein, and all applications for industrial property protection including, without limitation, all applications for patents, utility models, inventor's certificates and designs and rights of priority therein that may be filed for said Invention in any country, design registrations granted for any of said inventions or improvements, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; said interest being each of the Assignor's entire ownership interest in the same, to be held and enjoyed by said ASSIGNEE, its successors, assigns, or other legal representatives, to the full end of the term thereof, as fully and entirely as the same would have been held and enjoyed by each of the Assignor's if this Assignment and sale had not been made.

And for good and valuable consideration, the sufficiency of which is hereby acknowledges, we hereby covenant and agree to and with said ASSIGNEE, its successors and assigns, that whenever ASSIGNEE, its counsel or representative, or the counsel or representative of its successors or assigns, shall advise that an amendment to, or a division of, or any other proceeding or action in connection with an application concerning said Invention, including interference proceedings, is lawful and desirable, or that a reissue or continuation or extension of such application or patent issuing therefrom is lawful and desirable, Assignor will sign all papers and drawings, further applications, assignments, Preliminary Statements, take all rightful oaths and affidavits, and do all acts necessary or required to be done for the procurement or enforcement of all lawful rights associated with the Invention, or for the reissue or continuation or extension of the same, will do all acts necessary or required to secure in said ASSIGNEE, its successors or assigns, the title to and full benefit of all rights hereby assigned, without charge to said ASSIGNEE or its successors or assigns, but at its or their expense; and Assignor hereby appoint every present or future officer of said ASSIGNEE as my agent to sign all such papers and to do all such necessary acts on my behalf, to the fullest extent permitted by law.

This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

And Assignor hereby authorize and request the Commissioner of Patents and Trademarks and any other granting authority to issue any Letters Patent or other evidence or forms of industrial property protection resulting from said Invention and application(s) concerning same to said ASSIGNEE, its successors or assigns.


Assignor hereby grant the attorneys appointed in said application to insert in this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any other patent office for recordation of this document, including, but not limited to, inserting above the filing date and serial number of said application when known.

This Assignment shall have an effective date corresponding to the last date of execution.

Assignor hereby represents that Assignor has the full right to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict with this Assignment.

Assignor declares under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that Assignor has signed this document as their own free act and that all of the foregoing is true and correct.

ASSIGNOR



July 12, 2018

For: Albany Molecular Research, Inc.

Date

Witness:



July 12, 2018

Signature

Date

Henry Hagen

Printed name

ASSIGNEE

M.A. B.
For: Corbus Pharmaceuticals, Inc.

July 12, 2018
Date

Witness:

R.A. Discordia
Signature

July 12, 2018
Date

ROBERT A. DISCORDIA
Printed name